Normix (Rifaximin)

Rifaximin, the active ingredient in Normix, is a rifamycin‑class antibiotic presented as a 200 mg tablet for oral use. It targets gastrointestinal bacterial overgrowth and is indicated for conditions such as traveler’s diarrhea, hepatic encephalopathy, irritable bowel syndrome with diarrhea, and small intestinal bacterial overgrowth.

GNH USA supplies Normix as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU marketing authorisation standards and is manufactured under GMP conditions. It is distributed through GNH USA’s regulated supply chain, ensuring quality and traceability for global healthcare providers.

Rifaximin is an oral rifamycin antibiotic used to manage bacterial conditions of the gastrointestinal tract. - Traveler’s diarrhea: Reduces duration and severity of acute watery diarrhea caused by non‑invasive bacteria. - Hepatic encephalopathy: Lowers ammonia‑producing gut bacteria, helping to prevent recurrent episodes. - Irritable bowel syndrome with diarrhea: Improves stool consistency and reduces abdominal discomfort in IBS‑D patients. - Small intestinal bacterial overgrowth: Decreases bacterial load, alleviating bloating, gas and malabsorption symptoms.

Rifaximin may cause a range of adverse reactions, most of which are mild, reversible, and resolve after discontinuation.

Common Side Effects: - Nausea: mild stomach upset, usually transient. - Flatulence: increased intestinal gas and bloating. - Abdominal pain: cramping in the lower abdomen. - Diarrhea: loose stools during therapy. - Headache: mild, transient headache. - Vomiting: occasional emesis, self‑limiting. - Fatigue: feeling of tiredness.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis with watery diarrhea. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Severe neutropenia: markedly reduced white blood cells. - Persistent abdominal pain: may signal obstruction. - Pseudomembranous colitis: colon inflammation from toxin‑producing bacteria.

When prescribing rifaximin, clinicians should consider several precautionary measures to ensure safe use. - Indication verification: confirm the gastrointestinal bacterial infection matches approved uses. - Liver function: assess hepatic function before initiating therapy, especially in hepatic encephalopathy. - Renal impairment: use caution in patients with severe renal dysfunction. - Concomitant antibiotics: avoid unnecessary combination with other broad‑spectrum antibiotics to reduce resistance risk. - Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Rifaximin can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Cyclosporine: rifaximin reduces cyclosporine exposure, risking transplant rejection. - Carbamazepine: increased metabolism may lower carbamazepine levels, reducing seizure control.

Moderate Interactions (Monitor Closely): - Warfarin: possible alteration of INR, monitor coagulation. - Oral contraceptives: may decrease estrogen levels, advise additional contraception. - Statins (e.g., simvastatin): increased risk of myopathy, monitor muscle symptoms. - Antiretrovirals (e.g., ritonavir): may affect drug concentrations, adjust dosing as needed.